Dynavax Technologies Corporation stock is up 1.53% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 19 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 2 CALLs.
The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in the vaccine. The company was formerly known as Double Helix Corporation.